Pharmacological investigation of 'HIM-CHX'

A herbal combination in the experimental muscle wasting condition

Mohammed Mukhram Azeemuddin, Chamallamudi Mallikarjuna Rao, Mohamed Rafiq, Uddagiri Venkanna Babu, Paramesh Rangesh

Research output: Contribution to journalArticle

Abstract

Muscle wasting diseases are gradually increasing with the increase in global life expectancy. This study was designed to evaluate the efficacy of HIM-CHX, a herbal combination of Boswellia serrata, Cissus quadrangularis, and Withania somnifera, on Sarcopenia. The effects of HIM-CHX on parameters such as muscle mass, grip strength, motor coordination, gait, locomotor activity and endurance were measured in rats. In addition to this, inflammatory cytokines, myokine and growth hormone levels were also evaluated. In the first experiment, HIM-CHX was administered orally to rats at the dose of 125, 250, and 500 mg/kg body weight for 12 weeks. At the end of the treatment period, muscle mass, grip strength, motor coordination and proinflammatory cytokines were evaluated. In the second experiment, HIM-CHX was administered orally at a dose of 500 mg/kg body weight for 4 weeks and gait analysis, locomotor activity, endurance and endogenous antioxidant activity were evaluated. The animals treated with HIM-CHX showed a significant improvement in gastrocnemius muscle weight, carcass weight, gait, locomotor activity and endurance. HIM-CHX exerts its effect by reducing the levels of TNF-α, IL-6, and Myostatin while increasing the IGF-1 levels which are the typical biomarkers of muscle wasting. Furthermore, the study findings indicate that HIM-CHX has the potential to correct the pathophysiological changes associated with sarcopenia.

Original languageEnglish
Number of pages1
JournalExperimental Gerontology
Volume125
DOIs
Publication statusPublished - 01-10-2019

Fingerprint

Muscle
Locomotion
Gait
Pharmacology
Sarcopenia
Muscles
Hand Strength
Durability
Cissus
Boswellia
Withania
Body Weight
Myostatin
Rats
Cytokines
Wasting Syndrome
Weights and Measures
Gait analysis
Life Expectancy
Insulin-Like Growth Factor I

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Ageing
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Cell Biology

Cite this

Azeemuddin, Mohammed Mukhram ; Rao, Chamallamudi Mallikarjuna ; Rafiq, Mohamed ; Babu, Uddagiri Venkanna ; Rangesh, Paramesh. / Pharmacological investigation of 'HIM-CHX' : A herbal combination in the experimental muscle wasting condition. In: Experimental Gerontology. 2019 ; Vol. 125.
@article{e04f1b14a6ec421fbbce6bdefe21d57f,
title = "Pharmacological investigation of 'HIM-CHX': A herbal combination in the experimental muscle wasting condition",
abstract = "Muscle wasting diseases are gradually increasing with the increase in global life expectancy. This study was designed to evaluate the efficacy of HIM-CHX, a herbal combination of Boswellia serrata, Cissus quadrangularis, and Withania somnifera, on Sarcopenia. The effects of HIM-CHX on parameters such as muscle mass, grip strength, motor coordination, gait, locomotor activity and endurance were measured in rats. In addition to this, inflammatory cytokines, myokine and growth hormone levels were also evaluated. In the first experiment, HIM-CHX was administered orally to rats at the dose of 125, 250, and 500 mg/kg body weight for 12 weeks. At the end of the treatment period, muscle mass, grip strength, motor coordination and proinflammatory cytokines were evaluated. In the second experiment, HIM-CHX was administered orally at a dose of 500 mg/kg body weight for 4 weeks and gait analysis, locomotor activity, endurance and endogenous antioxidant activity were evaluated. The animals treated with HIM-CHX showed a significant improvement in gastrocnemius muscle weight, carcass weight, gait, locomotor activity and endurance. HIM-CHX exerts its effect by reducing the levels of TNF-α, IL-6, and Myostatin while increasing the IGF-1 levels which are the typical biomarkers of muscle wasting. Furthermore, the study findings indicate that HIM-CHX has the potential to correct the pathophysiological changes associated with sarcopenia.",
author = "Azeemuddin, {Mohammed Mukhram} and Rao, {Chamallamudi Mallikarjuna} and Mohamed Rafiq and Babu, {Uddagiri Venkanna} and Paramesh Rangesh",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.exger.2019.110663",
language = "English",
volume = "125",
journal = "Experimental Gerontology",
issn = "0531-5565",
publisher = "Elsevier Inc.",

}

Pharmacological investigation of 'HIM-CHX' : A herbal combination in the experimental muscle wasting condition. / Azeemuddin, Mohammed Mukhram; Rao, Chamallamudi Mallikarjuna; Rafiq, Mohamed; Babu, Uddagiri Venkanna; Rangesh, Paramesh.

In: Experimental Gerontology, Vol. 125, 01.10.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacological investigation of 'HIM-CHX'

T2 - A herbal combination in the experimental muscle wasting condition

AU - Azeemuddin, Mohammed Mukhram

AU - Rao, Chamallamudi Mallikarjuna

AU - Rafiq, Mohamed

AU - Babu, Uddagiri Venkanna

AU - Rangesh, Paramesh

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Muscle wasting diseases are gradually increasing with the increase in global life expectancy. This study was designed to evaluate the efficacy of HIM-CHX, a herbal combination of Boswellia serrata, Cissus quadrangularis, and Withania somnifera, on Sarcopenia. The effects of HIM-CHX on parameters such as muscle mass, grip strength, motor coordination, gait, locomotor activity and endurance were measured in rats. In addition to this, inflammatory cytokines, myokine and growth hormone levels were also evaluated. In the first experiment, HIM-CHX was administered orally to rats at the dose of 125, 250, and 500 mg/kg body weight for 12 weeks. At the end of the treatment period, muscle mass, grip strength, motor coordination and proinflammatory cytokines were evaluated. In the second experiment, HIM-CHX was administered orally at a dose of 500 mg/kg body weight for 4 weeks and gait analysis, locomotor activity, endurance and endogenous antioxidant activity were evaluated. The animals treated with HIM-CHX showed a significant improvement in gastrocnemius muscle weight, carcass weight, gait, locomotor activity and endurance. HIM-CHX exerts its effect by reducing the levels of TNF-α, IL-6, and Myostatin while increasing the IGF-1 levels which are the typical biomarkers of muscle wasting. Furthermore, the study findings indicate that HIM-CHX has the potential to correct the pathophysiological changes associated with sarcopenia.

AB - Muscle wasting diseases are gradually increasing with the increase in global life expectancy. This study was designed to evaluate the efficacy of HIM-CHX, a herbal combination of Boswellia serrata, Cissus quadrangularis, and Withania somnifera, on Sarcopenia. The effects of HIM-CHX on parameters such as muscle mass, grip strength, motor coordination, gait, locomotor activity and endurance were measured in rats. In addition to this, inflammatory cytokines, myokine and growth hormone levels were also evaluated. In the first experiment, HIM-CHX was administered orally to rats at the dose of 125, 250, and 500 mg/kg body weight for 12 weeks. At the end of the treatment period, muscle mass, grip strength, motor coordination and proinflammatory cytokines were evaluated. In the second experiment, HIM-CHX was administered orally at a dose of 500 mg/kg body weight for 4 weeks and gait analysis, locomotor activity, endurance and endogenous antioxidant activity were evaluated. The animals treated with HIM-CHX showed a significant improvement in gastrocnemius muscle weight, carcass weight, gait, locomotor activity and endurance. HIM-CHX exerts its effect by reducing the levels of TNF-α, IL-6, and Myostatin while increasing the IGF-1 levels which are the typical biomarkers of muscle wasting. Furthermore, the study findings indicate that HIM-CHX has the potential to correct the pathophysiological changes associated with sarcopenia.

UR - http://www.scopus.com/inward/record.url?scp=85071713303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071713303&partnerID=8YFLogxK

U2 - 10.1016/j.exger.2019.110663

DO - 10.1016/j.exger.2019.110663

M3 - Article

VL - 125

JO - Experimental Gerontology

JF - Experimental Gerontology

SN - 0531-5565

ER -